Logo image of CLGN

COLLPLANT BIOTECHNOLOGIES LT (CLGN) Stock Fundamental Analysis

NASDAQ:CLGN - Nasdaq - IL0004960188 - Common Stock - Currency: USD

3.47  -0.01 (-0.22%)

Fundamental Rating

3

Overall CLGN gets a fundamental rating of 3 out of 10. We evaluated CLGN against 572 industry peers in the Biotechnology industry. CLGN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. CLGN is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CLGN had negative earnings in the past year.
CLGN had a negative operating cash flow in the past year.
CLGN had negative earnings in 4 of the past 5 years.
CLGN had negative operating cash flow in 4 of the past 5 years.
CLGN Yearly Net Income VS EBIT VS OCF VS FCFCLGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 0 -5M -10M -15M

1.2 Ratios

CLGN's Return On Assets of -77.62% is on the low side compared to the rest of the industry. CLGN is outperformed by 68.38% of its industry peers.
With a Return On Equity value of -102.97%, CLGN perfoms like the industry average, outperforming 45.83% of the companies in the same industry.
Industry RankSector Rank
ROA -77.62%
ROE -102.97%
ROIC N/A
ROA(3y)-21.64%
ROA(5y)-44.39%
ROE(3y)-25.56%
ROE(5y)-95.67%
ROIC(3y)N/A
ROIC(5y)N/A
CLGN Yearly ROA, ROE, ROICCLGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 -50 -100 -150 -200 -250

1.3 Margins

CLGN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CLGN Yearly Profit, Operating, Gross MarginsCLGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 0 -1K -2K -3K -4K -5K

More info and screens

6

2. Health

2.1 Basic Checks

CLGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
CLGN has more shares outstanding than it did 1 year ago.
CLGN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CLGN Yearly Shares OutstandingCLGN Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M
CLGN Yearly Total Debt VS Total AssetsCLGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

2.2 Solvency

Based on the Altman-Z score of -4.46, we must say that CLGN is in the distress zone and has some risk of bankruptcy.
CLGN has a Altman-Z score (-4.46) which is in line with its industry peers.
CLGN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.46
ROIC/WACCN/A
WACC9.11%
CLGN Yearly LT Debt VS Equity VS FCFCLGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 20M 40M

2.3 Liquidity

CLGN has a Current Ratio of 5.38. This indicates that CLGN is financially healthy and has no problem in meeting its short term obligations.
CLGN has a Current ratio (5.38) which is comparable to the rest of the industry.
CLGN has a Quick Ratio of 5.23. This indicates that CLGN is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 5.23, CLGN is in line with its industry, outperforming 56.66% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.38
Quick Ratio 5.23
CLGN Yearly Current Assets VS Current LiabilitesCLGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

More info and screens

4

3. Growth

3.1 Past

CLGN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -126.67%.
Looking at the last year, CLGN shows a very negative growth in Revenue. The Revenue has decreased by -93.93% in the last year.
Measured over the past years, CLGN shows a quite strong growth in Revenue. The Revenue has been growing by 16.95% on average per year.
EPS 1Y (TTM)-126.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)-93.93%
Revenue growth 3Y21.3%
Revenue growth 5Y16.95%
Sales Q2Q%-90.7%

3.2 Future

Based on estimates for the next years, CLGN will show a very strong growth in Earnings Per Share. The EPS will grow by 24.82% on average per year.
CLGN is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.92% yearly.
EPS Next Y-219.3%
EPS Next 2Y6.03%
EPS Next 3Y24.82%
EPS Next 5YN/A
Revenue Next Year-89.02%
Revenue Next 2Y-6.73%
Revenue Next 3Y9.92%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
CLGN Yearly Revenue VS EstimatesCLGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 5M 10M 15M 20M
CLGN Yearly EPS VS EstimatesCLGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 -0.5 -1 -1.5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

CLGN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CLGN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CLGN Price Earnings VS Forward Price EarningsCLGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CLGN Per share dataCLGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

CLGN's earnings are expected to grow with 24.82% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.03%
EPS Next 3Y24.82%

More info and screens

0

5. Dividend

5.1 Amount

CLGN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

COLLPLANT BIOTECHNOLOGIES LT

NASDAQ:CLGN (2/21/2025, 8:09:58 PM)

3.47

-0.01 (-0.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-27 2024-11-27/bmo
Earnings (Next)04-02 2025-04-02/amc
Inst Owners18.09%
Inst Owner Change2.53%
Ins Owners33.2%
Ins Owner ChangeN/A
Market Cap39.73M
Analysts82.5
Price Target12.75 (267.44%)
Short Float %0.18%
Short Ratio1.36
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-32.53%
Min EPS beat(2)-34.35%
Max EPS beat(2)-30.72%
EPS beat(4)0
Avg EPS beat(4)-76.21%
Min EPS beat(4)-236.13%
Max EPS beat(4)-3.64%
EPS beat(8)1
Avg EPS beat(8)322.67%
EPS beat(12)1
Avg EPS beat(12)168.62%
EPS beat(16)2
Avg EPS beat(16)116.33%
Revenue beat(2)0
Avg Revenue beat(2)-69.01%
Min Revenue beat(2)-99.06%
Max Revenue beat(2)-38.97%
Revenue beat(4)0
Avg Revenue beat(4)-79.65%
Min Revenue beat(4)-99.06%
Max Revenue beat(4)-38.97%
Revenue beat(8)3
Avg Revenue beat(8)-28.72%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)25.68%
EPS NY rev (1m)0%
EPS NY rev (3m)-14.74%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-46%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.85%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 61.13
P/FCF N/A
P/OCF N/A
P/B 2.35
P/tB 2.37
EV/EBITDA N/A
EPS(TTM)-1.36
EYN/A
EPS(NY)-0.4
Fwd EYN/A
FCF(TTM)-1.19
FCFYN/A
OCF(TTM)-1.13
OCFYN/A
SpS0.06
BVpS1.48
TBVpS1.46
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -77.62%
ROE -102.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-21.64%
ROA(5y)-44.39%
ROE(3y)-25.56%
ROE(5y)-95.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 60.46%
Cap/Sales 100.46%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.38
Quick Ratio 5.23
Altman-Z -4.46
F-Score2
WACC9.11%
ROIC/WACCN/A
Cap/Depr(3y)138.43%
Cap/Depr(5y)154%
Cap/Sales(3y)152.96%
Cap/Sales(5y)106.31%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-126.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-219.3%
EPS Next 2Y6.03%
EPS Next 3Y24.82%
EPS Next 5YN/A
Revenue 1Y (TTM)-93.93%
Revenue growth 3Y21.3%
Revenue growth 5Y16.95%
Sales Q2Q%-90.7%
Revenue Next Year-89.02%
Revenue Next 2Y-6.73%
Revenue Next 3Y9.92%
Revenue Next 5YN/A
EBIT growth 1Y-157.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y4.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1.6%
OCF growth 3YN/A
OCF growth 5YN/A